Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2010-11-09
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07829575
ABSTRACT:
One embodiment is directed toward a method for treating an individual with a disorder affected by androgen receptor activity. This method includes administering a therapeutic amount of DL3 (6-amino-2-(2-4-tert-butyl-phenoxy)-ethylsulfanyl)-1H-pyrimidin-4-one) to the individual. In an additional embodiment, the disorder affected by androgen receptor activity includes cancer. Another embodiment is directed toward a method for treating an individual with prostate cancer. This method includes administering to the individual a therapeutic amount of an androgen receptor antagonist which reduces the production of prostate specific antigen and has only negligible androgen receptor agonist effects.
REFERENCES:
Carter et al. Chemotherapy of cancer, Second edition, 1981, A wiley Medical Publication John Wiley & Sons, pp. 361-369.
Yan et al, Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin, Molecular Endocrinology (1992), 2123-2128, 6:12.
Cohen et al, Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease, Journal of Endocrinology (1994), 407-415.
Fong et al, Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions, Prostate (1992), 21:121-131.
Yoshida et al, Prostate-specific antigen activates single-chain urokinase-type plasminogen activator, Int. J. Cancer (1995), 63:863-865.
Riegman et al, The promoter of the prostate-specific antigen gene contains a functional androgen responsive element, Molecular Endocrinology (1991), 1921-1930.
Kelly et al, Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome, Int. J. of Urology (1992), 607-609.
Crawford et al, Challenges in the management of prostate cancer, Br. J. Urol. (1992), 70 Suppl. 1:33-38.
Jemal A. Murray T., Ward E., et al, Cancer statistics, 2005. CA Cancer J. Clin 2005; 55(1):10-30.
Culig Z., Role of the androgen receptor axis in prostate cancer. Urology 2003; 62(5 Suppl 1):21-6.
Grossman M.E., Huang H., Tindall D.J., Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl Cancer Inst. 2001; 93(22):1687-97.
Scher H.I. Sawyers C.L., Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin Oncol 2005; 23(32):8253-61.
Best C.J., Gillespie J.W., Yi Y., et al., Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11(19 Pt 1):6823-34.
Eder I.E., Haag P., Basik M., et al., Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Mol Carcinog 2003;37(4):181-91.
Gregory C.W., Johnson R.T., Jr., Presnell S.C., Mohler J.L., French F.S., Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J. Androl 2001;22(4):537-48.
Lu S. Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997;57(20):4511-6.
Zhang M., Latham D.E., Delaney M.A., Chakravarti A., Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24(1 5):2474-82.
Mabjeesh N.J., Willard M.T., Frederickson C.E., Zhong H., Simons J.W., Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003:9(7):2416-25.
Pandini G., Mineo R., Frasca F., et al., Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005;65(5):1849-57.
Chen C.D., Welsbie D.S., Tran C., et al., Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9.
Balk S.P., Ko Y.J., Bubley G.J., Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383-91.
Diamandis E.P., Yousef G.M., Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48(8): 1198-205.
Webber M.M., Waghray A., Bello D.., Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995;1(10):1089-94.
Cramer S.D., Chen Z., Peehl D.M., Prostate specific antigen deaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol 1996;156(2 Pt 1):526-31.
Nadiminty N., Lou W, Lee S.O., et al., Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2. Clin Cancer Res 2006;12(5):1420-30.
Kim J., Coetzee G.A., Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004;93 (2):233-41.
Cleutjens K.B., van der Korput H.A., van Eekelen C.C., van Rooij H.C., Faber P.W., Trapman J., An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;1 1(2):148-61.
Schuur E.R., Henderson GA, Kmetec L.A., Miller J.D., Lamparski HG., Henderson D.R., Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996;271(12):7043-51.
Miyamoto H., Rahman M.M., Chang C., Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004;91(1):3-12.
Middleman MN., Lush R.M., Sartor O., Reed E., Figg W.D., Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treat Rev 1996;22(2):105-18.
Hara T., Miyazaki J., Araki H., et al., Novel mutations of androgen receptor a possible mechanism of bicalcutamide withdrawal syndrome. Cancer Res 2003;63(1):149-53.
Yoshida T., Kinoshita H., Segawa T., et al., Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65(21): 9611-6.
Huan S.D., Gerridzen R.G., Yau J.C., Steward D.J., Antiandrogen withdrawal syndrome with nilutamide. Urology 1997;49(4):632-4.
Small E.J., Carroll P.R., Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43(3):408-10.
Akakura K., Akimoto S., Ohki T., Shimazaki J., Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antlandrogen chlormadinone acetate. Urology 1995;45(4):700-4; discussion 4-5.
Sella A., Flex D., Sulkes A., Baniel J., Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 1998;52 (6):1091-3.
Horoszewicz J.S., Leong S.S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43 (4):1809-18.
Lu S., Tsai S.Y., Tsai M.J., Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 1999; 140(11):5054-9.
Jain A., Lam A., Vivanco I., Carey M.F., Reiter R.E., Identification of an androgen-dependent enhancer with the prostate stem cell antigen gene. Mol Encocrinol 2002; 16(10):2323-37.
Watt F., Martorana A., Brookes D.E., et al., A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001;73(3):243-54.
Murphy C., McGurk M.., Pettigrew J., et al., Nonapical and cytoplasmic expression of interleukin-8, CSCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005; 11(11): 4117-27.
Uehara H., Troncosco P., Johnston D., et al., Expression of interleukin-8 gene in radical prostatectomy specimen is associated with advance alpha pathologic state. Prostate 2005;64(1):40-9.
Lee C., Sutkowski D.M., Sensibar J.A., et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136(2)796-803.
Mohler J.L., Gregory C.W., Ford O.H., 3rd et al., The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440-8.
Sramkoski, R.M., Pretlow, T.G., 2nd, Giaconia, J.M., e
Dong Zhongyun
Lu Shan
Dinsmore & Shohl LLP
Kim Jennifer M
University of Cincinnati
LandOfFree
Methods for treating androgen receptor related disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating androgen receptor related disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating androgen receptor related disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237164